Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - dexchlorpheniramine maleate 0.4 mg/ml;   - syrup - 2 mg/5ml - active: dexchlorpheniramine maleate 0.4 mg/ml   excipient: apricot flavour 15502857 blood orange flavour sc481962 ethanol menthol methyl hydroxybenzoate ponceau 4r propyl hydroxybenzoate purified water sodium chloride sodium citrate dihydrate sorbitol sucrose - hayfever and year round allergies: sneezing, watery itchy eyes itchy skin from hives, insect bites.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) - transdermal patch - 25 mcg/24h - active: estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) - transdermal patch - 50 mcg/24h - active: estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Nuova Zelanda - inglese - Ministry for Primary Industries

bayer new zealand limited - fenoxaprop-p-ethyl - fenoxaprop-p-ethyl 69 g/litre - herbicide

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iloprost trometamol 20ug;   - solution for inhalation - 0.01 mg - active: iloprost trometamol 20ug   excipient: ethanol hydrochloric acid sodium chloride trometamol water for injection - treatment of patients with primary pulmonary hypertension or secondary pulmonary hypertension due to connective tissue disease or drug-induced, in moderate or severe stages of the disease. in addition, treatment of moderate or severe secondary pulmonary hypertension due to chronic pulmonary thromboembolism, where surgery is not possible.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - rivaroxaban 10mg - film coated tablet - 10 mg - active: rivaroxaban 10mg excipient: croscarmellose sodium hypromellose   iron oxide red lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - rivaroxaban 15mg - film coated tablet - 15 mg - active: rivaroxaban 15mg excipient: croscarmellose sodium hypromellose   iron oxide red lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age >= 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - rivaroxaban 20mg - film coated tablet - 20 mg - active: rivaroxaban 20mg excipient: croscarmellose sodium hypromellose   iron oxide red lactose monohydrate macrogol 3350 magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age >= 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.